1月13日,药明生物在第43届JP摩根医疗健康大会上分享了最新的业务进展:2024年,药明生物新增151个项目,较前年132个有进一步增长。药明生物披露,去年新签项目中超过一半来自于美国。2024年,由于行业融资遇冷,以及《美国生物安全法案》的影响,“药明系”整体都面临很大不确定性。2024年上半年,药明生物营收仅85.74亿元,同比仅微增0.97%,同期新增项目数约在75个左右,与下半年基本持平...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.